Macular Degeneration

Investigational New Drug application filed for macular degeneration trials

Published in Hepatitis Weekly, October 4th, 2004

Sirna Therapeutics, Inc., (NASDAQ:RNAI) announced that the company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) to begin trials of Sirna-027 in patients with age-related macular degeneration (AMD).

AMD is the leading cause of visual impairment affecting more than 1.5 million adults over the age of 50 in the United States. The filing of the IND is an important milestone for Sirna Therapeutics, the leader in RNA interference (RNAi) drug development, and it marks a significant next step in the company's plan to transition its platform RNAi technology from the research lab to patients.

Sirna-027...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-10-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry